Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in Stock

Key Points

• Major shareholder Bioventures 2018 L.P. Mpm sold 3,733 Entrada Therapeutics shares for $26,168 at an average price of $7.01, reducing its position by 0.09% to approximately 4.28 million shares. The shareholder also sold 44,259 shares on August 31 and 38,922 shares on August 27.
• Entrada Therapeutics shares traded at $7.05, near the lower end of their 52-week range of $5.02 to $16.45. The company missed quarterly EPS and revenue expectations, reporting a $1.01 loss per share and $0.90 million in revenue.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $17.75, although ratings range from Buy to Sell. Institutional investors own 86.39% of the company, with several funds establishing new positions during the second quarter.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $7.01, for a total value of $26,168.33. Following the completion of the sale, the insider directly owned 4,275,693 shares of the company's stock, valued at approximately $29,972,607.93. This trade represents a 0.09% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total value of $309,370.41.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.20, for a total value of $280,238.40.

Entrada Therapeutics Stock Performance

TRDA traded up $0.05 during midday trading on Monday, hitting $7.05. The stock had a trading volume of 450,412 shares, compared to its average volume of 325,154. Entrada Therapeutics, Inc. has a 1 year low of $5.02 and a 1 year high of $16.45. The business has a fifty day moving average of $7.08 and a 200 day moving average of $9.31. The company has a market cap of $274.51 million, a P/E ratio of -1.78 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The business had revenue of $0.90 million during the quarter, compared to analysts' expectations of $2.32 million. On average, equities research analysts anticipate that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on TRDA shares. Roth Capital restated a "buy" rating and set a $11.00 target price on shares of Entrada Therapeutics in a report on Wednesday, August 12th. HC Wainwright cut Entrada Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, May 8th. Weiss Ratings downgraded Entrada Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, August 13th. Finally, Guggenheim dropped their price objective on Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating for the company in a research note on Monday, June 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $17.75.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Odyssean LLC bought a new position in Entrada Therapeutics during the 2nd quarter valued at approximately $230,000. Nantahala Capital Management LLC bought a new stake in shares of Entrada Therapeutics in the 2nd quarter worth approximately $2,212,232. Public Employees Retirement System of Ohio bought a new stake in shares of Entrada Therapeutics in the 2nd quarter worth approximately $276,000. Bank of America Corp DE purchased a new position in shares of Entrada Therapeutics during the second quarter valued at approximately $426,000. Finally, 5AM Venture Management LLC purchased a new position in shares of Entrada Therapeutics during the second quarter valued at approximately $29,854,949. Hedge funds and other institutional investors own 86.39% of the company's stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source